# A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

> **NCT00416273** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag G.m.b.H** · enrollment: 217 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** No intervention

## Key facts

- **NCT ID:** NCT00416273
- **Lead sponsor:** Janssen-Cilag G.m.b.H
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00416273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00416273, "A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00416273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*